China-based MetaVision has completed another multi-million RMB funding round within two months of its June financing, with participation from Huaxi Jinzhi's specialised fund and existing investor JC Capital. The funds will support clinical registration, sales expansion and continued R&D of its AI-powered "light-eye-brain" neuromodulation system for myopia control. Clinical data from multi-centre trials showed MetaVision's products reduced axial length growth to 0.038mm over six months versus 0.125mm in controls, demonstrating superior efficacy to traditional methods.

The company has established industry standards for electronic distance-vision displays and built a network covering hundreds of medical institutions and over 1,000 retail outlets. It enjoyed 100% year-on-year revenue growth and profitability in H1 2025, with plans to upgrade core products and pursue Class III medical device registration.